Tags

Type your tag names separated by a space and hit enter

Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients.
Mov Disord. 2005 Jan; 20(1):69-72.MD

Abstract

Homocysteine (Hcy) is a risk factor for vascular diseases, cognitive impairment, and dementia. Elevated plasma concentrations of Hcy have been found recently in Parkinson's disease (PD) patients treated with levodopa, suggesting that levodopa is a cause of hyperhomocysteinemia (HHcy). The mechanism underlying HHcy in PD is the O-methylation of levodopa catalyzed by catechol-O-methyltransferase (COMT) that produces S-adenosylhomocysteine, which is hydrolyzed rapidly to Hcy. COMT inhibitors (COMT-I) are used currently in the treatment of PD; however, no study has assessed the effects of COMT-I administration on Hcy concentrations in PD patients. We compared plasma levels of Hcy, B12, and folate in 26 PD patients treated with levodopa, 20 PD patients treated with levodopa + COMT-I, and 32 controls. No significant differences were found in vitamin B12 levels, whereas folate concentrations were significantly lower in the levodopa-treated group. Plasma Hcy was increased significantly in the two groups of PD patients and was significantly lower in the group treated with levodopa + COMT-I. Statistical analysis showed that the difference in mean Hcy levels observed among PD patients was related to the addition of COMT-I, rather than to folate concentrations. We conclude that levodopa treatment increases plasma Hcy and the addition of COMT-I effectively reduces HHcy.

Authors+Show Affiliations

Department of Neurological Sciences, University of Bari, Bari, Italy. lamberti@neurol.uniba.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article

Language

eng

PubMed ID

15390046

Citation

Lamberti, Paolo, et al. "Effects of Levodopa and COMT Inhibitors On Plasma Homocysteine in Parkinson's Disease Patients." Movement Disorders : Official Journal of the Movement Disorder Society, vol. 20, no. 1, 2005, pp. 69-72.
Lamberti P, Zoccolella S, Iliceto G, et al. Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients. Mov Disord. 2005;20(1):69-72.
Lamberti, P., Zoccolella, S., Iliceto, G., Armenise, E., Fraddosio, A., de Mari, M., & Livrea, P. (2005). Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients. Movement Disorders : Official Journal of the Movement Disorder Society, 20(1), 69-72.
Lamberti P, et al. Effects of Levodopa and COMT Inhibitors On Plasma Homocysteine in Parkinson's Disease Patients. Mov Disord. 2005;20(1):69-72. PubMed PMID: 15390046.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients. AU - Lamberti,Paolo, AU - Zoccolella,Stefano, AU - Iliceto,Giovanni, AU - Armenise,Elio, AU - Fraddosio,Angela, AU - de Mari,Michele, AU - Livrea,Paolo, PY - 2004/9/25/pubmed PY - 2005/5/10/medline PY - 2004/9/25/entrez SP - 69 EP - 72 JF - Movement disorders : official journal of the Movement Disorder Society JO - Mov Disord VL - 20 IS - 1 N2 - Homocysteine (Hcy) is a risk factor for vascular diseases, cognitive impairment, and dementia. Elevated plasma concentrations of Hcy have been found recently in Parkinson's disease (PD) patients treated with levodopa, suggesting that levodopa is a cause of hyperhomocysteinemia (HHcy). The mechanism underlying HHcy in PD is the O-methylation of levodopa catalyzed by catechol-O-methyltransferase (COMT) that produces S-adenosylhomocysteine, which is hydrolyzed rapidly to Hcy. COMT inhibitors (COMT-I) are used currently in the treatment of PD; however, no study has assessed the effects of COMT-I administration on Hcy concentrations in PD patients. We compared plasma levels of Hcy, B12, and folate in 26 PD patients treated with levodopa, 20 PD patients treated with levodopa + COMT-I, and 32 controls. No significant differences were found in vitamin B12 levels, whereas folate concentrations were significantly lower in the levodopa-treated group. Plasma Hcy was increased significantly in the two groups of PD patients and was significantly lower in the group treated with levodopa + COMT-I. Statistical analysis showed that the difference in mean Hcy levels observed among PD patients was related to the addition of COMT-I, rather than to folate concentrations. We conclude that levodopa treatment increases plasma Hcy and the addition of COMT-I effectively reduces HHcy. SN - 0885-3185 UR - https://www.unboundmedicine.com/medline/citation/15390046/Effects_of_levodopa_and_COMT_inhibitors_on_plasma_homocysteine_in_Parkinson's_disease_patients_ L2 - https://doi.org/10.1002/mds.20261 DB - PRIME DP - Unbound Medicine ER -